- Published at
- by investing.com
mixed
mixed
Earnings call: Xeris Biopharma sees 26% revenue surge in Q2 2024 By Investing.com
Earnings call: Xeris Biopharma sees 26% revenue surge in Q2 2024
News for Xeris Pharmaceuticals, Inc. (0A8E.L)
- Published at
- by insidermonkey.com
positivepositiveXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
Operator: Hello everyone and welcome to the Xeris fourth quarter and full year 2023 financial results conference call and webcast. My name is Emily and I’ll be coordinating your call today.- Published at
- by insidermonkey.com
mixedmixedXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Call Transcript
Operator: Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I'll be operating your call today.- Published at
- by globenewswire.com
neutralneutralAutoinjectors Market Size to Surpass USD 233.69 Billion by 2030, exhibiting a CAGR of 11.2%
According to the report by Fortune Business Insights, the global autoinjectors market size is projected to reach USD 233.69 billion by 2030, at a CAGR of...- Published at
- by marketscreener.com
positivepositiveXeris Ships One Millionth Gvoke® Unit
Updated guidelines recognize the benefits of ready-to-use glucagon Protecting all people with diabetes at risk of severe hypoglycemia remains the goal ...- Published at
- by markets.businessinsider.com
positivepositiveFDA Grants Orphan-drug Exclusivity For Xeris' Recorlev For Endogenous Cushing's Syndrome Treatment
(RTTNews) - Xeris Biopharma Holdings Inc. (XERS) said Monday that the U.S. Food and Drug Administration granted its subsidiary Xeris Pharmaceutica...- Published at
- by prnewswire.com
mixedmixedGlobal Bio-Pharma Market is Expected to reach USD 703.28 Billion by 2027 at 12.5% CAGR, Says Brandessence Market Research
/PRNewswire/ -- Global Bio-Pharma Market is valued at USD 274.10 Billion in 2020 and is expected to reach USD 703.28 Billion by 2027 with a CAGR of 12.5% over...- Published at
- by etfdailynews.com
mixedmixedResearch Analysts’ Upgrades for May 19th (AAVMY, AAWW, AIT, AMOT, AMRN, AMZN, ATO, BCH, BCS, BECN)
Read Research Analysts’ Upgrades for May 19th (AAVMY, AAWW, AIT, AMOT, AMRN, AMZN, ATO, BCH, BCS, BECN) at ETF Daily NewsZLDPFZEALYUEIYYUEIFXGNWSFSVSSYWVS.CNVSVRTSVRSSFVODUPSTTUFNSWMAYSWMAFSTEM.LSSMXYSSMXFSRNESMARSBG-UNSBGPRLBPFSIOWLTOSHOROPGNOBSVN.MXOBSVOBSN.SWNICXFNEWTJMPLYJMPLFJMAT.LJEF.MXJEFITCBITAUCORP.SNHSBC.BAHSBC-PAHSBCHSBA.LHSB.PAHBCYFHBCN.MXHBC1.DEH1SB34.SACSCOCOX.PABECNAMZNAAVMY6869N.MX6869.T0RCQ.L0L85.L0KRR.L0GO4.L0A8L.L0551.HK0005.HKXERSXWPPUEPSUEUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSTACSYBXSGE.DESCGLYSCGLFRPMROPRMBSRCELPSALLPSA.MXPSA-PQPSA-PPPSAOSMTORKLYORKLFORK.OLOLKOCUPNTCTNKTXNDRAWNDRAMMYTMKTWLPTXLNNGYLNNGFLANCKNYJYKNYJFKC4.DEJPMMLJPMISSDYISFFFHEGSGI34.SAGS.MXGS.BAGSGOS.DEGLEN.MXGLE.PAFOJCYFOJCFFBIOEPREACTMXBCSBCHAVHHLAVH.AXATOAMOTAITACND-UNACND2331N.MX2331.HK0A8U.L0A8E.LDBN.MXDBK.PRDBK.MIDBK.DEDB- Published at
- by etfdailynews.com
mixedmixedXeris Biopharma (NASDAQ:XERS) Upgraded at Zacks Investment Research
Read Xeris Biopharma (NASDAQ:XERS) Upgraded at Zacks Investment Research at ETF Daily News- Published at
- by etfdailynews.com
positivepositive50,169 Shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Acquired by Ieq Capital LLC
Read 50,169 Shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Acquired by Ieq Capital LLC at ETF Daily News- Published at
- by marketscreener.com
mixedmixedXeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's Syndrome
FDA approval supported by positive results from the pivotal Phase 3 SONICS and LOGICS studies demonstrating Recorlev to be a safe and effective therapeutic option in the treatment of Cushing's... | December 30, 2021- Published at
- by thestreet.com
mixedmixedXeris Biopharma Announces U.S. FDA Approval Of Recorlev® (levoketoconazole) For The Treatment Of Endogenous Hypercortisolemia In Adult Patients With Cushing's Syndrome
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in- Published at
- by markets.businessinsider.com
mixedmixed60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ:TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pf...XERSVVOSVTOLTRIL.TOTRILSTTKRMOREKRPXLWNRXPNMTCDNMTCMSGE.MXMSGEMMATLMRKPLMRKOLMRKNLMRKICVXHYREHUNGFHNP.BAHNPGRNQGOEVFLXNEQEDITDVAXDOCSCTIBCLSKCIO-PACIOCATBCASICANBYSIBNTXN.MXBNTXBMEABFLY-WTBFLYBCYCBASEALXOABVC600011.SS0IFK.L0IDA.L0A8E.L0A4D.L0A3M.L0902.HKVLDRWVLDRVINCWVINCUVINCSPRTNUVB-WTNUVBEOSEWEOSEENDPCADL0Y5F.LPMCBDPMCBKLXE